AstraZeneca PLC (LON: AZN, NASDAQ: AZN) reported better-than-expected second-quarter earnings as strong growth in oncology and rare diseases helped offset weaker sales in other parts of the business.
AstraZeneca Slides 9.2% After Wainua Misses Primary Goal in Phase Three Trial
AstraZeneca has seen around £20 billion wiped from its market value following the disappointing late-stage trial results for Wainua, pushing its market capitalisation below £200 billion.
AstraZeneca CEO Cautions Against Imposing Tariffs on Pharmaceuticals
AstraZeneca’s Chief Executive Officer, Pascal Soriot, has cautioned that trade tariffs are ineffective in managing the pharmaceutical sector, as drug manufacturers express concern over potential U.S. duties.
AstraZeneca plans £2bn investment in Beijing despite ongoing China investigation
AstraZeneca has announced plans to invest £2 billion in Beijing, just months after Chinese authorities detained the head of its China division over alleged illegal activities.
AstraZeneca experiences a £2.8 billion reduction in its value due to concerns over expenses.
Shares of AstraZeneca PLC (LSE: AZN) dropped by 1.8%, leading to a £2.8 billion decrease in the company’s market value. This decline was primarily due to ongoing concerns about the
AstraZeneca (LON:AZN) set to acquire a Chinese pharmaceutical company in a multi-billion dollar agreement.
AstraZeneca PLC (LON: AZN) is poised to complete a substantial acquisition, purchasing Gracell Biotechnologies, a Chinese firm renowned for its innovative therapies targeting cancer and autoimmune diseases, in a deal
AstraZeneca enhances its earnings amid the emergence of legal proceedings related to vaccines.
AstraZeneca surpassed profitability expectations as it disclosed its third-quarter earnings, even as it confronts a significant legal challenge alleging that the effectiveness of its vaccines was greatly exaggerated.
AstraZeneca (LON:AZN) reaches a monthly peak due to positive outcomes from a breast cancer medication trial.
Shares of AstraZeneca PLC (LSE: AZN) have witnessed a 2% increase, surpassing 11,100p for the first time in a month, following the company’s announcement of promising results from an ongoing
AstraZeneca (LON:AZN) and Alexion collaborate with the FDA to broaden the US label for Ultomiris.
AstraZeneca PLC (LON: AZN) announced that the US Food and Drug Administration (FDA) has requested a risk assessment and mitigation strategy in response to a proposal to broaden the application
AstraZeneca subsidiary finalizes a US$1bn deal with Pfizer for rare diseases.
AstraZeneca has reported a stronger-than-anticipated performance in the second quarter, with robust sales from its leading cancer drugs offsetting the decline in Covid vaccine sales.